Advertisement

Potential of gadolinium as contrast material in second generation dual energy computed tomography – An ex vivo phantom study

Published:February 23, 2017DOI:https://doi.org/10.1016/j.clinimag.2017.02.005

      Highlights

      • DECT-based low-keV monoenergetic extrapolation increases attenuation of gadolinium containing contrast material significantly.
      • Equivalent contrast and half SNR of standard dose ICM are achievable with 0.5 mmol/kg body weight GdCM.
      • DECT-based computation of gadolinium-VNC images, gadolinium maps and the quantification of gadolinium is accurately possible.

      Abstract

      Purpose

      To evaluate the potential of gadolinium (Gd) as contrast material (CM) in second generation dual energy computed tomography (DECT).

      Material and methods

      In a phantom model, DECT post-processing was used to increase Gd attenuation using advanced monoenergetic extrapolation (MEI), to create virtual non-contrast images (Gd-VNC) and Gd maps and to quantify Gd content. Dilutions of Gd and iodinated CM (7–296 HU) were filled in syringes, placed in an attenuation phantom and scanned with standard DECT protocols (80 &100/Sn140 kV). MEI (40–190 keV) and VNC images as well as Gd maps were computed. The amount of Gd was quantified and the accuracy was compared to iodine images. Linear regression models were calculated to evaluate Gd attenuation of equivolume CM doses and clinical MRI doses.

      Results

      Applying monoenergetic reconstructions and using Gd as contrast agent (Gd MEI 40 keV) doubled Hounsfield-Units (HU) and 90% of the SNR (averaged: 225 HU, SNR3.1) are achievable, as compared to iodinated CM at 120 kV (averaged:110 HU, SNR3.5), at Gd doses of 1.0 mmol/kg BW. The accuracies of Gd-VNC (deviation, 6 ± 12 HU) images and Gd quantification (measurement error, 17%) were not significantly different to those of iodine enhanced images (VNC:deviation, 2 ± 11 HU; measurement error,14%).

      Conclusion

      Using monoenergetic extrapolation at 40 keV, it is possible to increase Gd-CM attenuation significantly. Thus, equivalent HU and half the SNR in comparison to a standard dose of ICM at 120 kV can be expected at a Gd-CM dose of 0.5 mmol/kg BW. Post-processing features of iodine based DECT like monoenergetic or VNC images, iodine maps or quantification of CM are feasible with the use of Gd-CM.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Clinical Imaging
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Mortele K.J.
        • Oliva M.R.
        • Ondategui S.
        • et al.
        Universal use of nonionic iodinated contrast medium for CT: evaluation of safety in a large urban teaching hospital.
        AJR Am J Roentgenol. 2005; 184: 31-34
        • Rydahl C.
        • Thomsen H.S.
        • Marckmann P.
        High prevalence of nephrogenic systemic fibrosis in chronic renal failure patients exposed to gadodiamide, a gadolinium-containing magnetic resonance contrast agent.
        Invest Radiol. 2008; 43: 141-144
        • Janus N.
        • Launay-Vacher V.
        • Karie S.
        • et al.
        Prevalence of nephrogenic systemic fibrosis in renal insufficiency patients: results of the FINEST study.
        Eur J Radiol. 2010; 73: 357-359
        • Chrysochou C.
        • Buckley D.L.
        • Dark P.
        • et al.
        Gadolinium-enhanced magnetic resonance imaging for renovascular disease and nephrogenic systemic fibrosis: critical review of the literature and UK experience.
        J Magn Reson Imaging. 2009; 29: 887-894
        • Sam 2nd, A.D.
        • Morasch M.D.
        • Collins J.
        • et al.
        Safety of gadolinium contrast angiography in patients with chronic renal insufficiency.
        J Vasc Surg. 2003; 38: 313-318
        • Filippi M.
        • Rovaris M.
        • Capra R.
        • et al.
        A multi-centre longitudinal study comparing the sensitivity of monthly MRI after standard and triple dose gadolinium-DTPA for monitoring disease activity in multiple sclerosis. Implications for phase II clinical trials.
        Brain. 1998; 121: 2011-2020
        • Engelbrecht V.
        • Koch J.A.
        • Rassek M.
        • et al.
        Gadodiamide and gadolinium-DTPA as intravenous media in computed tomography.
        Rofo. 1996; 165: 24-28
        • Luboldt W.
        • De Santis M.
        • von Smekal A.
        • et al.
        Attenuation characteristics and application of gadolinium-DTPA in fast helical computed tomography.
        Invest Radiol. 1997; 32: 690-695
        • Gul K.M.
        • Mao S.S.
        • Gao Y.
        • et al.
        Noninvasive gadolinium-enhanced three dimensional computed tomography coronary angiography.
        Acad Radiol. 2006; 13: 840-849
        • Grant K.L.
        • Flohr T.G.
        • Krauss B.
        • et al.
        Assessment of an advanced image-based technique to calculate virtual monoenergetic computed tomographic images from a dual-energy examination to improve contrast-to-noise ratio in examinations using iodinated contrast media.
        Invest Radiol. 2014; 49: 586-592
        • Schabel C.
        • Bongers M.
        • Sedlmair M.
        • et al.
        Assessment of the hepatic veins in poor contrast conditions using dual energy CT: evaluation of a novel monoenergetic extrapolation software algorithm.
        Rofo. 2014; 186: 591-597
        • Bongers M.N.
        • Schabel C.
        • Krauss B.
        • et al.
        Noise-optimized virtual monoenergetic images and iodine maps for the detection of venous thrombosis in second-generation dual-energy CT (DECT): an ex vivo phantom study.
        Eur Radiol. 2014;
        • Yu L.
        • Christner J.A.
        • Leng S.
        • et al.
        Virtual monochromatic imaging in dual-source dual-energy CT: radiation dose and image quality.
        Med Phys. 2011; 38: 6371-6379
        • Purysko A.S.
        • Primak A.N.
        • Baker M.E.
        • et al.
        Comparison of radiation dose and image quality from single-energy and dual-energy CT examinations in the same patients screened for hepatocellular carcinoma.
        Clin Radiol. 2014; 69: e538-e544
        • Liu Y.
        • Ai K.
        • Lu L.
        Nanoparticulate X-ray computed tomography contrast agents: from design validation to in vivo applications.
        Acc Chem Res. 2012; 45: 1817-1827
        • Chanda N.
        • Upendran A.
        • Boote E.J.
        • et al.
        Gold nanoparticle based X-ray contrast agent for tumor imaging in mice and dog: a potential nano-platform for computer tomography theranostics.
        J Biomed Nanotechnol. 2014; 10: 383-392
        • Reuveni T.
        • Motiei M.
        • Romman Z.
        • et al.
        Targeted gold nanoparticles enable molecular CT imaging of cancer: an in vivo study.
        Int J Nanomedicine. 2011; 6: 2859-2864
        • Zeng C.
        • Shi X.
        • Wu B.
        • et al.
        Colloids containing gadolinium-capped gold nanoparticles as high relaxivity dual-modality contrast agents for CT and MRI.
        Colloids Surf B Biointerfaces. 2014; 123: 130-135
        • Nowak T.
        • Hupfer M.
        • Brauweiler R.
        • et al.
        Potential of high-Z contrast agents in clinical contrast-enhanced computed tomography.
        Med Phys. 2011; 38: 6469-6482
        • Prince M.R.
        • Arnoldus C.
        • Frisoli J.K.
        Nephrotoxicity of high-dose gadolinium compared with iodinated contrast.
        J Magn Reson Imaging. 1996; 6: 162-166
        • Wack C.
        • Steger-Hartmann T.
        • Mylecraine L.
        • et al.
        Toxicological safety evaluation of gadobutrol.
        Invest Radiol. 2012; 47: 611-623
        • Bae K.T.
        Intravenous contrast medium administration and scan timing at CT: considerations and approaches.
        Radiology. 2010; 256: 32-61